（文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：公司降脂药创新药目前BD谈判到底进展如何？ 京新药业（002020.SZ）12月11日在投资者互动平台表示，LP（a）机制降脂新药的对外授权工作进展 中，公司会努力推进，若有进展敬请关注相关公告。 ...

Core Viewpoint - The company is currently in the clinical I phase for its LP(a) lowering drug, and the external licensing work is progressing, with updates to be provided through official announcements [1] Group 1 - An investor inquired about the progress of the company's LP(a) lowering drug BD business, expressing concerns about the perceived slow efficiency [1] - The company confirmed that the LP(a) lowering drug is in the clinical I phase and that the external licensing efforts are ongoing [1]

Group 1 - The company currently has several innovative drugs in clinical trials, including JX11502 capsules, rehabilitation new enteric-coated capsules, and LP(a) mechanism lipid-lowering drugs [2] - The company has expressed interest in overseas business development for some of its innovative drugs [2] - The company assures that its pipeline for innovative drug development is robust and sufficient for future growth [2]